Baxter International BAX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
As of March 31, 2026, we had $8.87 billion of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of more than one year, which are primarily included in the Medical Products & Therapies segment. Some contracts in the United States included in this amount contain index-dependent price increases, which are not known at this time. We expect to recognize approximately 25% of this amount as revenue over the remainder of 2026, 20% in 2027, 15% in each of 2028 and 2029, 10% in 2030 and the remainder thereafter.
Item 1. Financial Statements (unaudited)
FAQ
- What is Baxter International's deferred revenue?
- Baxter International (BAX) reported deferred revenue of $8.87B in Q1 2026.
- How has Baxter International's deferred revenue changed year-over-year?
- Baxter International's deferred revenue decreased by 13.0% year-over-year, from $10.19B to $8.87B.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Baxter International's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
